ASCO: Selpercatinib Improves Event-Free Survival in RET Fusion-Positive NSCLC

TUESDAY, June 2, 2026 -- For patients with RET fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC), the rearranged during transfection (RET) inhibitor, selpercatinib, yields significantly longer event-free survival, according...